| Abstrak/Abstract |
Diabetes mellitus is one the chronic disease with a large number of sufferers. The
World Health Organization (WHO) predicts an increase in diabetes mellitus
patients, particularly type 2, to reach 21,3 million by the year 2030. Several
therapeutic recommendations have been implemented for the management of type
2 DM. In Indonesia, these recommendations are guided by the Regulation of the
Ministry of Health of the Republic of Indonesia (HK. 01.07/Menkes/603/2020).
The initial therapy for type 2 DM is through the use of metformin, but in certain
cases, such as having an HbA1C value > 7.5% or being intolerant to monotherapy,
combination therapy as a second line treatment can be employed. The Most
commonly used combination drugs with metformin are insulin and sulfonylurea.
The use of there drugs in undoubtedly associated with economic factors. The
healthcare costs for type 2 DM medications in Indonesia are quite high, thus
necessitating an analysis of the cost-effectiveness of combination therapy drugs
such as glimepiride-metformin, glibenclamide-metformin, and insulin-metformin.
This research is based on observational retrospective design, conducted at Bali
Mandara General Hospital, Bali. Data were extracted from hospital records of
outpatient type 2 diabetes mellitus patients during the priod from January 2020 to
December 2023. Effectiveness data were obtained from patient medical records,
and costs data were collected from hospital financial records. Consecutive sampling
was used as the sampling method. The independent variables in this study are the
types of combination drug therapies used, and the dependent variables are therapy
effectiveness and direct medical costs. Data analysis was performed by calculating
the values of ACER and ICER to identify the most cost-effective therapy. Patient
characteristics were analyzed using univariate analysis, while effectiveness and
direct medical costs data underwent multivariate testing with ANNOVA |
